Better Defining Growth Medium to Improve Reproducibility of Cell Culture (SBIR) (R43/R44 - Clinical Trial Not Allowed) | PA 18 815

Opportunity Information: Apply for PA 18 815

The NIH grant opportunity "Better Defining Growth Medium to Improve Reproducibility of Cell Culture" (PA-18-815) is an SBIR solicitation designed for small businesses to create practical tools that reduce a long-standing source of inconsistency in cell culture research: reliance on fetal bovine serum (FBS). FBS is popular because it is relatively inexpensive and broadly effective at supporting growth and survival across many cell lines, but it is also notoriously variable from lot to lot. That variability can change what cells do in culture, affecting growth rates, signaling pathways, gene expression patterns, and other physiological behaviors. As a result, two labs running the "same" experiment can end up with different outcomes simply because their serum differs, which contributes to poor reproducibility and unreliable comparisons across studies.

The core purpose of this funding announcement is to support the development of novel, reliable, and cost-effective technologies that help researchers either standardize serum-based culture conditions or replace serum altogether. In practice, this means the NIH is looking for innovations that make cell culture media more defined and predictable, so experiments become easier to reproduce across time, batches, and laboratories. The emphasis on tools suggests the program is oriented toward product-oriented R and D that can be adopted broadly by the research community, such as assays, measurement platforms, quality-control methods, or improved media supplements that reduce dependence on undefined serum components. Because the FOA focuses on improving reproducibility, proposed solutions would generally be expected to address the sources of variability in serum composition and activity and translate that into more consistent cell culture performance.

This is a discretionary grant program under the NIH and uses the SBIR funding mechanism R43/R44, which typically corresponds to a phased approach: early feasibility and prototype development followed by further development and validation, with the intent of moving toward commercialization. The opportunity is explicitly "Clinical Trial Not Allowed," meaning projects should not be structured as clinical trials; the work should remain in the preclinical and technology-development space (for example, bench validation, analytical testing, cell-based performance benchmarking, and similar non-clinical evaluations). The activity category is health, and it is listed under CFDA (now Assistance Listing) 93.859.

Eligibility is limited to small businesses. Foreign institutions (non-U.S. entities) are not eligible to apply, and non-U.S. components of U.S. organizations are also not eligible. However, foreign components may be allowed in some cases as defined by the NIH Grants Policy Statement, which generally means a U.S. applicant might be able to include certain clearly justified foreign elements within a predominantly U.S.-based project, subject to NIH rules and approvals.

Key administrative details included in the source information are: the funding opportunity title as above, the opportunity number PA-18-815, the agency as the National Institutes of Health, and the original closing date listed as 2021-04-05. The record does not provide an award ceiling or expected number of awards in the provided fields, so applicants would typically need to consult the full FOA text and NIH SBIR budget guidelines for the relevant limits, phase structure, and submission requirements. Overall, the program is aimed at enabling more standardized cell culture conditions by reducing dependence on variable serum inputs, thereby improving the reliability and reproducibility of biomedical research that depends on cultured cells.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Better Defining Growth Medium to Improve Reproducibility of Cell Culture (SBIR) (R43/R44 - Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.859.
• This funding opportunity was created on 2018-06-05.
• Applicants must submit their applications by 2021-04-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for PA 18 815

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: